Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer

Pembrolizumab in men with heavily treated metastatic castrate‐resistant prostate cancer

Abstract Background Pembrolizumab is approved for patients with metastatic, microsatellite instability (MSI)‐high or mismatch repair‐deficient (dMMR) solid tumors. However, very few men with prostate cancer were included in these initial studies. Methods We performed a single institution retrospecti...

Full description

Bibliographic Details
Main Authors: Matthew D. Tucker, Jason Zhu, Daniele Marin, Rajan T. Gupta, Santosh Gupta, William R. Berry, Sundhar Ramalingam, Tian Zhang, Michael Harrison, Yuan Wu, Patrick Healy, Stacey Lisi, Daniel J. George, Andrew J. Armstrong
Format: Article
Language:English
Published: Wiley 2019-08-01
Series:Cancer Medicine
Subjects:
genomic profiling
LRP1b
mCRPC
pembrolizumab
prostate cancer
Online Access:https://doi.org/10.1002/cam4.2375

Internet

https://doi.org/10.1002/cam4.2375

Similar Items